Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma, Kaposi 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1HIV Infections 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Specimen Handling 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × Antiretroviral Therapy, Highly Active × Clear all
NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡